Table 2 Opioid dose requirements, buprenorphine dose, and time-weighted average pain scores for 48 h postoperatively. Summary statistics presented as N (%) of patients, mean ± SD, or median [IQR]
Buprenorphine continued (n=121) | Buprenorphine discontinued (n=199) | P value | |
|---|---|---|---|
Postoperative opioid dose in MME, excluding buprenorphine | 88 [20–157] | 194 [69–343] | < 0.001 |
Postoperative buprenorphine dose in mg | 28.0 [12.0–40.0] | N/A | N/A |
Time-weighted average pain score | 5.3 ± 2.4 | 6.2 ± 1.9 | <0.001 |
Length of hospital stay in days | 6 [4–10] | 6 [4–13] | 0.31 |
Respiratory depression, N (%) | 33 (27.3) | 46 (23.1) | 0.40 |
Respiratory rate < 10/minute | 11 (9.1) | 15 (7.5) | 0.62 |
SpO2 < 90% | 26 (21.5) | 36 (18.1) | 0.46 |
Requirement of naloxone | 0 (0) | 0 (0) | - |
Respiratory complications, N (%) | 13 (10.7) | 38 (19.1) | 0.048 |
Pulmonary insufficiency following trauma and surgery | 0 (0) | 1 (0.5) | |
Other pulmonary insufficiency, not elsewhere classified | 0 (0) | 0 (0) | |
Acute respiratory failure | 3 (2.5) | 13 (6.5) | |
Other respiratory anomalies | 0 (0) | 0 (0) | |
Pulmonary collapse | 1 (0.8) | 5 (2.5) | |
Pneumococcal pneumonia | 0 (0) | 0 (0) | |
Other bacterial pneumonia | 0 (0) | 0 (0) | |
Bronchopneumonia, organism unspecified | 0 (0) | 0 (0) | |
Pneumonia, organism uspecified | 1 (0.8) | 1 (0.5) | |
Respiratory arrest | 0 (0) | 0 (0) | |
Apnea | 0 (0) | 0 (0) | |
Acute respiratory distress syndrome | 2 (1.7) | 1 (0.5) | |
Respiratory failure, unspecified, unspecified whether with hypoxia or hypercapnia | 1 (0.8) | 5 (2.5) | |
Atelectasis | 8 (6.6) | 21 (10.6) | |
Other pulmonary collapse | 2 (1.7) | 2 (1.0) | |
Pneumonia due to Streptococcus pneumoniae | 0 (0) | 0 (0) | |
Pneumonia due to Hemophilus influenzae | 0 (0) | 0 (0) | |
Bacterial pneumonia, not elsewhere classified | 1 (0.8) | 0 (0) | |
Pneumonia, unspecified organism | 8 (6.6) | 11 (5.5) | |
Apnea, not elsewhere classified | 0 (0) | 0 (0) |